OR WAIT null SECS
Under the collaboration, Avantor and GeminiBio will offer custom cGMP solutions to enhance process efficiency and accelerate speed-to-market of novel emerging therapy modalities.
Avantor has entered into an agreement with GeminiBio, a US-based supplier of cell culture products, instruments, and solutions, to deliver custom hydrated solutions and cell culture media, the companies announced on June 23, 2022.
Under the agreement, Avantor's manufacturing platforms will complement GeminiBio's small-to-medium-scale product offering, with the goal of supplying customized current good manufacturing practice (cGMP) products through the full development lifecycle—from early stage research to scale-up and commercialization. Custom hydrated solutions and cell culture media are critical components in the bioproduction workflow, particularly for emerging modalities such as gene therapy.
"With the imperative to meet patient needs quickly, our customers require custom solutions to accelerate their bioproduction goals," said Ger Brophy, executive vice president, Biopharma Production, Avantor, in a company press release. "Customized media is critical in optimizing cell line productivity, and hydrated solutions offer efficiency to biomanufacturers as they optimize their downstream processes. Our collaboration with GeminiBio will drive increases in product yields, helping bring efficiency and speed to our customers as they scale."
"Enabling customers to optimize their upstream and downstream liquid manufacturing workflows by offering custom solutions, built around a strong quality foundation, has been an essential part of GeminiBio's success. Collaborating with Avantor, who shares our focus on quality, will allow us to expand our ability to address customer needs for both small- and large-volume process liquids," said Brian Parker, CEO of GeminiBio, in the press release.